TeleMAb Retrospective Cohort Study

NCT07405294 | Active Not Recruiting

• 1 other identifier: AAAV5073
• Study Type: observational
• Target: 400
• Locations: 1 country
• Sites: 1

Brief Summary

The objective of this study is to evaluate whether there are different clinical outcomes and unscheduled follow-ups between in-person and telemedicine medication abortion, and to better understand patients' experiences with telemedicine medication abortion and their motivations for seeking unscheduled follow-up care in a setting where abortion care, including both virtual and in-person follow-up care, is readily accessible.

Conditions

Medication Abortion; Telemedicine

Outcome Measures

Primary Outcomes (1)

• Number of unscheduled follow-ups

  If patients engaged in follow-up are outside of their routinely scheduled follow-up visit 1-2 weeks after medication abortion

  3 months after initial encounter

Study Arms (2)

Telemedicine Med Ab

Patients who received medication abortion through the telemedicine medication abortion service during the study period.

Other: Telemedicine Medication Abortion

In-person Med Ab

Patients who received an in-person medication abortion at the clinic during the study period.

Interventions

Telemedicine Medication Abortion OTHER

Meeting with a clinician via video visit to determine if patient is eligible for medication abortion without pre-treatment ultrasound or laboratory testing. If eligible, the patient travels to clinic to pick up medications in person.

Telemedicine Med Ab

Eligibility Criteria

• Sex: female
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Biologically female patients of reproductive age with an unwanted pregnancy seeking care at Columbia University's family planning clinics and interested in medication abortion.

You may qualify if:

• Received telemedicine or in-person medication abortion at Columbia University Irving Medical Center's associated practices from June 12, 2023 through September 30, 2024
• Gestational age \<70 days (based on best obstetrical dating)
• English or Spanish speaking

You may not qualify if:

• Received mifepristone and misoprostol for early pregnancy loss
• Patient determined to have contraindication to medication abortion
• Opted for procedural management instead of medication abortion
• Decided to continue with the pregnancy
• Presenting for a second medication abortion at CUIMC during the study period
• Non-English or Spanish speaking

Sponsors & Collaborators

• Columbia University: lead

Study Sites (1)

Columbia University Irving Medical Center

New York, New York, 10032-3720, United States

Location

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Wyeth-Ayerst Associate Professor of Women's Health in Obstetrics and Gynecology

Study Record Dates

• First Submitted: February 4, 2026
• First Posted: February 12, 2026
• Study Start: June 12, 2023
• Primary Completion: November 15, 2025
• Study Completion (Estimated): July 31, 2026
• Last Updated: February 12, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)